{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:38:11Z","timestamp":1773272291565,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disorders. Dupilumab, the first targeted biological drug approved for the treatment of AD, has been widely used, along with increasing ocular adverse effects (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To perform a bibliometric analysis of all the qualified literature involving ocular AEs during the treatment of AD with dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant studies were extracted from the Web of Science database and screened by researchers. The bibliographic analysis was performed using the VOSviewer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 138 articles were enrolled in this study. The first study was published in 2016 by Oregon Health and Science University from the United States. The majority of publications were published in the past 3 years. <jats:italic>British Journal of Dermatology<\/jats:italic> published the highest number of articles. The United States was the country with the most publications. Sanofi (France) and Regeneron Pharmaceuticals (USA) were the leading organizations with the most contributions. Conjunctivitis was the most common ocular AE. The management of AD will continue to be the research hotspot and development trend in this area. The milestone research is the first article \u201cTwo Phase 3 Trials of Dupilumab vs. Placebo in Atopic Dermatitis\u201d published in the <jats:italic>New England Journal of Medicine<\/jats:italic>. Most of the top 10 papers were mainly randomized, placebo-controlled phase 2 and phase 3 clinical trials and real-life large cohort studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study may help better understand ocular AEs in the dupilumab treatment of AD, and grasp the research trends and most influential topics in this field.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.802036","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:59:02Z","timestamp":1646290742000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Qian-Nan","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the global burden of disease study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","article-title":"The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 national health and wellness survey","volume":"78","author":"Eckert","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2332\/allergolint.13-RAI-0564","article-title":"New insights into atopic dermatitis: role of skin barrier and immune dysregulation","volume":"62","author":"Leung","year":"2013","journal-title":"Allergol Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1358\/dot.2017.53.9.2693150","article-title":"Dupilumab: human monoclonal antibody against IL-4R\u03b1 for moderate to severe atopic dermatitis","volume":"53","author":"Paton","year":"2017","journal-title":"Drugs Today."},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2147\/DDDT.S113192","article-title":"Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy","volume":"11","author":"D'Erme","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","article-title":"Retrospective analysis of adverse events with dupilumab reported to the United States food and drug administration","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1111\/jdv.15807","article-title":"Acquired hypersensitivity to dupilumab: first case report","volume":"33","author":"Ludriksone","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: a systematic review","author":"Brumfiel","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1111\/jdv.16094","article-title":"Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution","volume":"34","author":"Zhu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.20138","article-title":"Dupilumab-associated arthralgia: an observational retrospective study in VigiBase","volume":"185","author":"Chr\u00e9tien","year":"2021","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report","volume":"5","author":"Zirwas","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2019.06.1308","article-title":"The most cited articles and authors in dermatology: a bibliometric analysis of 1974-2019","volume":"83","author":"Maymone","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/jid.2011.391","article-title":"A review of the journal of investigative dermatology's most cited publications over the past 25 years and the use of developing bibliometric methodologies to assess journal quality","volume":"132","author":"Bickers","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fonc.2021.629687","article-title":"Research interest and public interest in melanoma: a bibliometric and google trends analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e13134","DOI":"10.1111\/dth.13134","article-title":"Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin","volume":"32","author":"Sernicola","year":"2019","journal-title":"Dermatol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of IgE and TARC but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1773379","article-title":"A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis","author":"Fargnoli","year":"2020","journal-title":"J Dermatolog Treat."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.802036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:59:05Z","timestamp":1646290745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.802036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":32,"alternative-id":["10.3389\/fmed.2022.802036"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.802036","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"article-number":"802036"}}